Also known as: AT-1001
A tight-junction regulator developed for celiac disease and "leaky gut".
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Blocks zonulin signaling so the gaps between intestinal cells stay closed.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Gut health | B | Human trials (smaller, mixed, or approved outside the US) |
At a glance
- Route
- Oral capsule
- Half-life
- Acts locally in gut
Reported dosing
0.5 mg three times daily (trial dose).
Timing: 15 minutes before each meal.
Cycle: Trials ran 12 weeks.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Headache, mild GI upset
Who should avoid it
- Not a replacement for a gluten-free diet
Often combined with
Alone.
Key findings
Phase 2 reduced symptoms at 0.5 mg. Phase 3 was stopped in 2022 after an interim look showed it was unlikely to beat placebo.
Where it is legal (Oct 2026)
| US | Not approved |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open Larazotide in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.